FrancophonIA/ELRC3.0 huggingface dataset:
English: Dapagliflozin plus metformin
Slovenian: Dapagliflozin skupaj z metforminom
English: Change from baseline Difference from glipizide + metformin c
Slovenian: Razlika v primerjavi s kombinacijo glipizid + metformin
English: Xigduo 5 mg/850 mg film-coated tablets Polyvinyl alcohol (E1203) Macrogol 3350 (E1521) Talc (E553b)
Slovenian: Xigduo 5 mg/850 mg filmsko obložene tablete polivinilalkohol (E1203) makrogol 3350 (E1521) smukec (E553b) titanov dioksid (E171) rumeni železov oksid (E172) rdeči železov oksid (E172)
English: Skin and subcutaneous tissue disorders
Slovenian: Bolezni mišičnoskeletnega sistema in vezivnega tkiva bolečine v hrbtu
English: Nephropathy
Slovenian: Nefropatija
English: Mean difference in change from baseline between combination and single active agent (95% CI)
Slovenian: Odstotek spremembe od izhodišča Razlika v odstotku spremembe v primerjavi s placebom (95 % IZ)
English: Very common Common Uncommon
Slovenian: Zelo pogosti Pogosti
English: How to store Xigduo
Slovenian: Shranjevanje zdravila Xigduo
English: Musculoskeletal and
Slovenian: • mišične krče
English: Each tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 1,000 mg of metformin hydrochloride.
Slovenian: Ena tableta vsebuje dapagliflozin-propandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 1000 mg metforminijevega klorida.
English: Rash includes the following preferred terms, listed in order of frequency in clinical trials: rash, rash generalised, rash pruritic, rash macular, rash maculo-papular, rash pustular, rash vesicular, and rash erythematous.
Slovenian: Izpuščaj vključuje naslednje prednostne izraze, naštete v zaporedju po pogostnosti v kliničnih preskušanjih: izpuščaj, generaliziran izpuščaj, srbeč izpuščaj, makularen izpuščaj, makulo-papularen izpuščaj, pustularen izpuščaj, vezikularen izpuščaj in eritematozen izpuščaj.
English: Xigduo 5 mg/850 mg tablets dapagliflozin/metformin HCl
Slovenian: Xigduo 5 mg/850 mg tablete dapagliflozin/metforminijev klorid
English: Xigduo 5 mg/1,000 mg tablets dapagliflozin/metformin HCl
Slovenian: Xigduo 5 mg/1000 mg tablete dapagliflozin/metforminijev klorid
English: The combination treatment with dapagliflozin 10 mg and prolonged-release exenatide group showed superior reductions in HbA1c from baseline compared to dapagliflozin alone and prolonged-release exenatide alone (Table 8).
Slovenian: V primerjavi s samim dapagliflozinom ali samim eksenatidom v obliki s podaljšanim sproščanjem je kombinirano zdravljenje z 10 mg dapagliflozina in eksenatidom v obliki s podaljšanim sproščanjem bolj znižalo HbA1c v primerjavi z izhodiščem (preglednica 8).
English: *,b,c
Slovenian: *,b,c okužba sečil
English: Urticaria Erythema Pruritus
Slovenian: Bolezni kože in podkožja izpuščaj urtikarija eritem srbenje
English: Evidence of sustained glucose excretion was seen in subjects with type 2 diabetes mellitus given dapagliflozin 10 mg/day for up to 2 years.
Slovenian: Pri bolnikih s sladkorno boleznijo tipa 2, ki so dobivali 10 mg dapagliflozina na dan do 2 leti, so ugotovili konstantno izločanje glukoze.
English: Xigduo 5 mg/1,000 mg film-coated tablets dapagliflozin/metformin hydrochloride
Slovenian: Xigduo 5 mg/1000 mg filmsko obložene tablete dapagliflozin/metforminijev klorid
English: • constipation
Slovenian: • bruhanje
English: Xigduo 5 mg/850 mg film-coated tablets dapagliflozin/metformin hydrochloride
Slovenian: Xigduo 5 mg/850 mg filmsko obložene tablete dapagliflozin/metforminijev klorid
English: Metformin (immediate- or extended-release formulations) ≥ 1500 mg/day plus maximum tolerated dose, which must be at least half maximum dose, of a sulphonylurea for at least 8 weeks prior to enrolment.
Slovenian: Metformin (v obliki s takojšnjim ali podaljšanim sproščanjem) ≥ 1500 mg/dan ter največji tolerirani odmerek (ki je moral biti vsaj polovica največjega odmerka) sulfonilsečnine, vsaj 8 tednov pred vključitvijo Randomizirani in zdravljeni bolniki z izhodiščno in vsaj še 1 poizhodiščno meritvijo učinkovitosti HbA1c analiziran z LRM (analiza longitudinalnih ponavljajočih se meritev) Povprečje najmanjših kvadratov, korigirano za izhodiščno vrednost Vrednost p < 0,0001 v primerjavi s kombinacijo placebo + peroralni antidiabetik (antidiabetiki)
English: Placebo BID
Slovenian: Placebo enkrat na dan
English: Mean percent change from baseline for dapagliflozin 10 mg versus placebo, respectively, was: total cholesterol 2.5% versus 0.0%; HDL cholesterol 6.0% versus 2.7%; LDL cholesterol 2.9% versus -1.0%; triglycerides -2.7% versus -0.7%.
Slovenian: Povprečni odstotek spremembe od izhodišča za 10 mg dapagliflozina v primerjavi s placebom je bil: celotni holesterol 2,5 % v prim.
English: A 24-week study in 182 diabetic subjects using dual energy X-ray absorptiometry (DXA) to evaluate body composition demonstrated reductions with dapagliflozin 10 mg plus metformin compared with placebo plus metformin, respectively, in body weight and body fat mass as measured by DXA rather than lean tissue or fluid loss.
Slovenian: Ugotovili so, da je 10 mg dapagliflozina v kombinaciji z metforminom zmanjšalo telesno maso in telesno maščevje v primerjavi s kombinacijo placeba in metformina, brez zmanjšanja mršavega tkiva ali izgube tekočin.
English: Results at Week 52 (LOCF a) in an active-controlled study comparing dapagliflozin with glipizide as add-on to metformin
Slovenian: Rezultati z učinkovino kontrolirane študije, ki je primerjala dapagliflozin z glipizidom kot dodatkom metforminu po 52 tednih (LOCF
English: At Weeks 24, HbA1c change from baseline in subjects treated with dapagliflozin plus insulin with metformin was -0.93%.
Slovenian: Po 24 tednih se je HbA1c pri preiskovancih, zdravljenih z dapagliflozinom v kombinaciji z insulinom in metforminom, v primerjavi z izhodiščem spremenil za
English: Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in subjects with type 2 diabetes mellitus following the administration of dapagliflozin.
Slovenian: Pri zdravih osebah in bolnikih s sladkorno boleznijo tipa 2 se je po uporabi dapagliflozina povečala količina glukoze, izločene z urinom.
English: HbA1c analysed using LRM (Longitudinal repeated measures analysis) Least squares mean adjusted for baseline value p-value < 0.0001 versus placebo + oral glucose-lowering medicinal product(s)
Slovenian: LOCF: prenos zadnjega opažanja [Last observation carried forward] Randomizirani in zdravljeni preiskovanci z izhodiščno in vsaj še eno poizhodiščno meritvijo učinkovitosti Povprečje najmanjših kvadratov, korigirano za izhodiščno vrednost Neinferiorno v primerjavi s kombinacijo glipizid + metformin Vrednost p < 0,0001
English: Baseline (mean) Change from baseline Difference from placebo d
Slovenian: Izhodišče (povprečje) Sprememba od izhodišča Razlika v primerjavi s placebom d
English: Blood urea increased Weight decreased
Slovenian: **,b zvišanje sečnine v krvi zmanjšanje telesne mase
English: Dapagliflozin 5 mg BID
Slovenian: Dapagliflozin 5 mg dvakrat na dan
English: Baseline (mean) Change from Baseline Difference from Placebo c
Slovenian: Izhodišče (povprečje) Sprememba od izhodišča Razlika v primerjavi s placebom c
English: OTHER
Slovenian: c
English: PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING
Slovenian: PODATKI NA VMESNI OVOJNINI
English: Coadministration of dapagliflozin and metformin
Slovenian: Sočasna uporaba dapagliflozina in metformina
English: Annex A
Slovenian: Priloga A
English: Oral use bottle (glass)
Slovenian: 6 mg/ml prašek za peroralno suspenzijo peroralna uporaba steklenica (steklo)
English: Treatment with conventional or biological medicines had not worked in these patients.
Slovenian: Zdravljenje s konvencionalnimi ali biološkimi zdravili pri teh bolnikih ni bilo učinkovito.
English: To make this medicine, the cells are selected and cultivated in the laboratory to increase their number.
Slovenian: Pri izdelavi tega zdravila se celice izberejo in gojijo v laboratoriju, da se poveča njihovo število.
English: This is a type of medicine that contains cells or tissues that have been modified so that they can be used to cure, diagnose or prevent a disease.
Slovenian: Gre za skupino zdravil, ki vsebujejo celice ali tkiva, ki so bili spremenjeni tako, da se lahko uporabljajo za zdravljenje, diagnosticiranje ali preprečevanje bolezni.
English: What measures are being taken to ensure the safe and effective use of Alofisel?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Alofisel?
English: This is a summary of the European public assessment report (EPAR) for Alofisel.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Alofisel.
English: Data on the safety of Alofisel are limited but they provide enough information on the pattern of side effects.
Slovenian: Podatki o varnosti zdravila Alofisel so omejeni, vendar zagotavljajo dovolj informacij o vzorcu neželenih učinkov.
English: The European Medicines Agency decided that Alofisel's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Alofisel večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
English: Other information about Alofisel
Slovenian: Druge informacije o zdravilu Alofisel
English: Of the patients treated with Alofisel, combined remission occurred in almost 50% of patients (53 out of 107); this compared with 34% of patients (36 out of 105) receiving placebo.
Slovenian: Do kombinirane remisije je prišlo pri skoraj 50 % (53 od 107) bolnikov, zdravljenih z zdravilom Alofisel, in pri 34 % (36 od 105) bolnikov, ki so prejemali placebo.
English: When injected into the walls of the fistula, these cells can help to reduce inflammation and support the growth of new tissue.
Slovenian: Ko se celice injicirajo v stene fistule, lahko zmanjšajo vnetje in podpirajo rast novega tkiva.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Alofisel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Slovenian: Povzetek mnenja Odbora za zdravila sirote o zdravilu Alofisel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Alofisel is given just once.
Slovenian: Zdravilo Alofisel se da samo enkrat.
English: This encourages the fistula to heal and close.
Slovenian: To pripomore k celjenju in zapiranju fistule.
English: After preparing the fistulas for treatment in an operating room, the contents of two vials (each containing 30 million cells) are injected around the internal openings and two further vials through the external openings into the walls of the fistula.
Slovenian: Po pripravi fistul za zdravljenje v operacijski dvorani se v okolico notranjih odprtin injicira vsebina dveh vial (od katerih vsaka vsebuje 30 milijonov celic), vsebina dveh dodatnih vial pa se injicira skozi zunanje odprtine v stene fistule.
English: The patient is given an anaesthetic (either to put the patient to sleep or to numb the treatment area).
Slovenian: Bolnik prejme anestetik (ki uspava bolnika ali omrtviči zdravljeni predel).
English: The company will also complete a study to continue to collect information on the effectiveness and safety of Alofisel.
Slovenian: Izvedla bo tudi študijo, s katero bo zbrala še več informacij o učinkovitosti in varnosti tega zdravila.
English: The main measure of effectiveness, called ‘combined remission', was the closing of abnormal external openings together with lack of fluid collections of more than 2 cm associated with internal passages (since these are likely to re-open the fistula).
Slovenian: Glavno merilo učinkovitosti, imenovano kombinirana remisija, je bilo zaprtje nenormalnih zunanjih odprtin in odsotnost notranjih prehodov, večjih od 2 cm, napolnjenih s tekočino (ker obstaja verjetnost, da bodo fistulo ponovno odprli).
English: It is not intended to provide practical advice on how to use Alofisel.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What are the risks associated with Alofisel?
Slovenian: Kakšna tveganja so povezana z zdravilom Alofisel?
English: Because the number of patients with anal fistula is low, the disease is considered ‘rare', and Alofisel was designated an ‘orphan medicine' (a medicine used in rare diseases) on 8 October 2009.
Slovenian: Ker je bolnikov z analnimi fistulami malo, velja ta bolezen za redko, zato je bilo zdravilo Alofisel 8. oktobra 2009 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: Alofisel must not be used in patients with hypersensitivity (allergy) to bovine serum (the clear liquid in blood from cattle) or to any of the ingredients of Alofisel.
Slovenian: Zdravila Alofisel ne smejo uporabljati bolniki s preobčutljivostjo za (alergijo na) goveji serum (bistro tekočino v krvi, pridobljeno iz goveda) ali katero koli sestavino zdravila.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Alofisel have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Alofisel upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The company that markets Alofisel will provide educational material for healthcare professionals on how to give the medicine correctly and on the possibility of passing on an infection to the patient.
Slovenian: Družba, ki trži zdravilo Alofisel, bo zdravstvenim delavcem priskrbela izobraževalno gradivo o pravilnem dajanju zdravila in možnosti prenosa okužbe na bolnika.
English: What is Alofisel and what is it used for?
Slovenian: Kaj je zdravilo Alofisel in za kaj se uporablja?
English: What benefits of Alofisel have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Alofisel izkazalo v študijah?
English: Why is Alofisel approved?
Slovenian: Zakaj je bilo zdravilo Alofisel odobreno?
English: Alofisel should be given only by specialist doctors experienced in the diagnosis and treatment of the condition for which it is used.
Slovenian: Zdravilo Alofisel smejo dajati samo zdravniki specialisti z izkušnjami v diagnostiki in zdravljenju bolezni, za katero se uporablja.
English: For more information about treatment with Alofisel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Alofisel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Complex fistulas are those with several abnormal passages and openings, or with passages that go deep inside the body, or where there are other complications such as collection of pus.
Slovenian: Zapletene fistule so fistule z več nenormalnimi prehodi in odprtinami ali s prehodi, ki segajo globoko v telo, ali stanja z več zapleti, kot so ognojki.
English: The full EPAR for Alofisel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Alofisel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: One main study, involving 212 patients with Crohn's disease and complex anal fistulas, found Alofisel more effective than placebo (a dummy treatment) 24 weeks after treatment.
Slovenian: V glavni študiji, ki je vključevala 212 bolnikov s Crohnovo boleznijo in zapletenimi analnimi fistulami, so ugotovili, da je zdravilo Alofisel po 24 tednih zdravljenja učinkovitejše od placeba (zdravila brez zdravilne učinkovine).
English: It is a type of advanced therapy medicine called a ‘somatic cell therapy product'.
Slovenian: Zdravilo spada v skupino zdravil za napredno zdravljenje, ki se imenujejo „zdravila za somatsko celično zdravljenje“.
English: Alofisel is of value in the treatment of complex anal fistulas that have not responded well to other treatments.
Slovenian: Zdravilo Alofisel je pomembno pri zdravljenju zapletenih analnih fistul, ki se ne odzovejo na druga zdravljenja.
English: Fistulas are abnormal passages between the lower parts of the gut and the skin near the anus.
Slovenian: Fistule so nenormalni prehodi med spodnjimi deli črevesja in kožo v analnem predelu.
English: Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease (an inflammatory condition of the gut) when a conventional or biological medicine has not worked well enough.
Slovenian: Zdravilo Alofisel se uporablja pri zdravljenju zapletenih analnih fistul pri odraslih s Crohnovo boleznijo (črevesno vnetno boleznijo), kadar konvencionalna ali biološka zdravila niso dovolj učinkovita.
English: For practical information about using Alofisel, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Alofisel naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: The most common side effects with Alofisel (which may affect up to 1 in 10 people) are anal abscess (a swollen area with a collection of pus), proctalgia (anal pain), anal fistula and pain during treatment.
Slovenian: Najpogostejši neželeni učinki zdravila Alofisel (ki se lahko pojavijo pri največ 1 bolniku od 10) so analni absces (oteklina z ognojkom), proktalgija (analna bolečina), analna fistula in bolečine med zdravljenjem.
English: Alofisel contains the active substance darvadstrocel, which comprises stem cells removed from fat tissue of adult donors.
Slovenian: Zdravilo Alofisel vsebuje zdravilno učinkovino darvadstrocel, ki je sestavljeno iz matičnih celic, pridobljenih iz maščobnega tkiva odraslih darovalcev.
English: How is Alofisel used?
Slovenian: Kako se zdravilo Alofisel uporablja?
English: Alofisel is made up of ‘mesenchymal stem cells' from the fat tissue of a donor.
Slovenian: Zdravilo Alofisel je narejeno iz mezenhimskih matičnih celic, pridobljenih iz maščobnega tkiva darovalca.
English: How does Alofisel work?
Slovenian: Kako zdravilo Alofisel deluje?
English: 30 film-coated tablets in blisters
Slovenian: 30 filmsko obloženih tablet v pretisnih omotih
English: The marketing authorisation was renewed on 18 August 2003 and on 18 August 2008.
Slovenian: Dovoljenje za promet z zdravilom je bilo obnovljeno 18. avgusta 2003 in 18. avgusta 2008.
English: The dose is adjusted to give the best control.
Slovenian: Odmerek se prilagodi, da se omogoči čim boljši nadzor.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Prandin to Novo Nordisk A/S on 29 January 2001.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Prandin, veljavno po vsej Evropski uniji, odobrila družbi Novo Nordisk A/S dne 29. januarja 2001.
English: Prandin is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Slovenian: Zdravilo Prandin ni priporočljivo za bolnike, mlajše od 18 let, zaradi pomanjkanja informacij o varnosti in učinkovitosti zdravila v tej starostni skupini.
English: Prandin is taken before meals, normally up to 15 minutes before each main meal.
Slovenian: Zdravilo Prandin se jemlje pred obroki, običajno do 15 minut pred vsakim glavnim obrokom.
English: Other information about Prandin:
Slovenian: Druge informacije o zdravilu Prandin:
English: It is available as round tablets (white: 0.5 mg; yellow: 1 mg; peach: 2 mg).
Slovenian: Na voljo je v obliki okroglih tablet (bele: 0,5 mg; rumene: 1 mg: barve breskve: 2 mg).
English: If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Slovenian: Če bolniki preidejo z drugega antidiabetičnega zdravila, je priporočeni začetni odmerek 1 mg.
English: What benefit has Prandin shown during the studies?
Slovenian: Kakšne koristi je zdravilo Prandin izkazalo med študijami?
English: Prandin is a medicine that contains the active substance repaglinide.
Slovenian: Prandin je zdravilo, ki vsebuje zdravilno učinkovino repaglinid.
English: If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Če potrebujete več informacij o svojem zdravstvenem stanju ali zdravljenju, preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujete s svojim zdravnikom ali farmacevtom.
English: Another study looked at the effect of adding Prandin to metformin.
Slovenian: Druga študija je preučevala učinek dodajanja zdravila Prandin k metforminu.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PRANDIN EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) PRANDIN Povzetek EPAR za javnost
English: The Committee recommended that Prandin be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Prandin odobri dovoljenje za promet.
English: The raised insulin levels returned to normal after the meal.
Slovenian: Zvečana koncentracija insulina se je po obroku vrnila na normalno raven.
English: A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Slovenian: Zdravnik mora redno preverjati bolnikovo glukozo v krvi, da določi najmanjši učinkoviti odmerek.
English: Prandin has been studied in 45 ‘clinical pharmacology' studies (looking at how the medicine works in the body) and 16 clinical trials (looking at its effects in treating type 2 diabetes patients).
Slovenian: Zdravilo Prandin so preučevali v 45 kliničnih farmakoloških študijah (v katerih so preučevali, kako zdravilo deluje v telesu) in 16 kliničnih preskušanjih (v katerih so preučevali njegove učinke pri zdravljenju bolnikov s sladkorno boleznijo tipa 2).
English: In the study where Prandin was added to metformin, the effects of the two medicines were at least additive (equivalent to the effects of the two medicines added together).
Slovenian: V študijah, v katerih so zdravilo Prandin dodali metforminu, so bili učinki dveh zdravil najmanjši (enaki učinkom dveh zdravil, dodanih skupaj).
English: Prandin should not be used in people who may be hypersensitive (allergic) to repaglinide or any of the other ingredients.
Slovenian: Zdravila Prandin ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) repaglinid ali katero koli drugo sestavino zdravila.
English: A total of 2,156 patients received Prandin in all trials combined.
Slovenian: V vseh preskušanjih skupaj je zdravilo Prandin prejelo 2156 bolnikov.
English: Prandin doses may also need to be adjusted when given with some medicines used in heart conditions, and to treat pain, asthma and other conditions.
Slovenian: Odmerke zdravila Prandin bo morda treba tudi prilagoditi, če se uporabljajo z zdravili za zdravljenje bolezni srca, bolečin, astme in drugih bolezni.
English: The main studies compared Prandin with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
Slovenian: V glavnih študijah so zdravilo Prandin primerjali z drugimi zdravili, uporabljenimi za zdravljenje sladkorne bolezni tipa 2 (glibenklamid, glipizid ali gliklazid).
English: What is the risk associated with Prandin?
Slovenian: Kakšna tveganja so povezana z zdravilom Prandin?
English: Why has Prandin been approved?
Slovenian: Zakaj je bilo zdravilo Prandin odobreno?
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Slovenian: Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne tvori dovolj insulina za uravnavanje koncentracije glukoze v krvi ali kadar telo ne more učinkovito izrabljati insulina.